MX394263B - Proceso de replegamiento mejorado para los fragmentos de anticuerpo - Google Patents

Proceso de replegamiento mejorado para los fragmentos de anticuerpo

Info

Publication number
MX394263B
MX394263B MX2018001994A MX2018001994A MX394263B MX 394263 B MX394263 B MX 394263B MX 2018001994 A MX2018001994 A MX 2018001994A MX 2018001994 A MX2018001994 A MX 2018001994A MX 394263 B MX394263 B MX 394263B
Authority
MX
Mexico
Prior art keywords
antibody fragments
refolding process
ranibizumab
enhanced refolding
enhanced
Prior art date
Application number
MX2018001994A
Other languages
English (en)
Other versions
MX2018001994A (es
Inventor
Ashish Pandey
Ashok Mishra
Rustom Sorab Mody
Sandeep Somani
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of MX2018001994A publication Critical patent/MX2018001994A/es
Publication of MX394263B publication Critical patent/MX394263B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a un proceso de replegamiento de Ranibizumab, en donde la disolución solubilizada de cadena pesada y/o cadena ligera de Ranibizumab tratada con un búfer de replegamiento en condiciones adecuadas que incluyen pH, temperatura y periodo de incubación y el cambio de pH y temperatura se realiza a intervalos adecuados para obtener alta calidad y cantidad de la proteína replegada.
MX2018001994A 2015-08-17 2016-08-17 Proceso de replegamiento mejorado para los fragmentos de anticuerpo MX394263B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3118MU2015 2015-08-17
PCT/IB2016/054926 WO2017029620A1 (en) 2015-08-17 2016-08-17 An improved refolding process for antibody's fragments

Publications (2)

Publication Number Publication Date
MX2018001994A MX2018001994A (es) 2018-11-09
MX394263B true MX394263B (es) 2025-03-24

Family

ID=56936450

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001994A MX394263B (es) 2015-08-17 2016-08-17 Proceso de replegamiento mejorado para los fragmentos de anticuerpo

Country Status (19)

Country Link
US (1) US10781250B2 (es)
EP (1) EP3337820B1 (es)
JP (1) JP6755939B2 (es)
CN (1) CN108026165A (es)
AU (1) AU2016307976A1 (es)
CA (1) CA2993907A1 (es)
DK (1) DK3337820T3 (es)
ES (1) ES2843558T3 (es)
HK (1) HK1254752A1 (es)
HR (1) HRP20210067T1 (es)
HU (1) HUE052993T2 (es)
LT (1) LT3337820T (es)
MX (1) MX394263B (es)
PH (1) PH12018500362B1 (es)
PL (1) PL3337820T3 (es)
PT (1) PT3337820T (es)
RU (1) RU2018109102A (es)
WO (1) WO2017029620A1 (es)
ZA (1) ZA201801498B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
EP3601332A1 (en) * 2017-03-24 2020-02-05 Council of Scientific and Industrial Research A process for the purification of recombinant antibody fragments
KR102607655B1 (ko) * 2017-05-19 2023-11-28 카운슬 오브 사이언티픽 앤드 인더스트리얼 리서치 리폴딩된 재조합 인간화 라니비주맙의 제조 방법
CA3114802A1 (en) * 2018-10-11 2020-04-16 Amgen Inc. Downstream processing of bispecific antibody constructs
CN111128293B (zh) * 2019-11-25 2020-11-10 苏州纽博立科技有限公司 一种抗体药物生产工艺中碎片的修复方法
CN113073092A (zh) * 2021-04-15 2021-07-06 宁波瑞林生物科技有限公司 重组人组织型激肽释放酶及其制备方法
EP4673455A1 (en) * 2023-03-01 2026-01-07 Lupin Limited Process for manufacturing antibody fragment protein

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
EP1819730A2 (en) 2004-11-30 2007-08-22 Novo Nordisk A/S Method of producing antibodies
CN100336824C (zh) * 2005-12-19 2007-09-12 百奥泰生物科技(广州)有限公司 一种重组蛋白的高效变复性的方法
CN103251947B (zh) * 2006-07-10 2017-11-21 艾斯巴技术-诺华有限责任公司 穿过上皮和/或内皮层的scFV抗体
CA2656835C (en) * 2006-07-14 2017-12-19 Genentech, Inc. Refolding of recombinant proteins
EP2281827B1 (en) * 2008-05-08 2013-08-21 Ajinomoto Co., Inc. Protein refolding method
CN102206272B (zh) * 2009-12-11 2014-10-01 普罗特奥姆技术公司 生产重组α1-抗胰蛋白酶的方法
US20130273607A1 (en) * 2010-10-20 2013-10-17 Medimmune, Llc Methods for processing inclusion bodies
WO2014126884A1 (en) * 2013-02-12 2014-08-21 Bristol-Myers Squibb Company High ph protein refolding methods
CA2911087A1 (en) * 2013-04-30 2014-11-06 Harish Shandilya Novel cloning, expression & purification method for the preparation of ranibizumab
CN103804486B (zh) * 2014-01-20 2017-05-17 安徽安科生物工程（集团）股份有限公司 一种提高重组人干扰素α2b天然构象含率的制备工艺

Also Published As

Publication number Publication date
MX2018001994A (es) 2018-11-09
AU2016307976A1 (en) 2018-03-08
US20180230206A1 (en) 2018-08-16
PT3337820T (pt) 2021-01-19
EP3337820A1 (en) 2018-06-27
JP6755939B2 (ja) 2020-09-16
PH12018500362B1 (en) 2022-08-05
JP2018529654A (ja) 2018-10-11
HK1254752A1 (zh) 2019-07-26
LT3337820T (lt) 2021-02-10
DK3337820T3 (da) 2021-01-18
RU2018109102A3 (es) 2020-01-30
ZA201801498B (en) 2018-12-19
PH12018500362A1 (en) 2018-08-29
HUE052993T2 (hu) 2021-06-28
CN108026165A (zh) 2018-05-11
WO2017029620A1 (en) 2017-02-23
PL3337820T3 (pl) 2021-11-22
RU2018109102A (ru) 2019-09-19
EP3337820B1 (en) 2020-10-14
HRP20210067T1 (hr) 2021-03-05
US10781250B2 (en) 2020-09-22
ES2843558T3 (es) 2021-07-19
CA2993907A1 (en) 2017-02-23

Similar Documents

Publication Publication Date Title
MX394263B (es) Proceso de replegamiento mejorado para los fragmentos de anticuerpo
MX2024015440A (es) Anticuerpos anti-phf-tau y usos de estos
CL2018000744A1 (es) Anticuerpos anti-tigit (inmunoreceptor de linfocitos t con dominios ig e itim) y metodos de uso.
EA201600252A1 (ru) Модифицированные антитела к рецепторам антиэпидермального фактора роста и способы их использования
EA201792589A1 (ru) Антитела против cd123 и конъюгаты указанных антител
PE20170665A1 (es) Anticuerpos anti-tau humanizados
UY36942A (es) Proteínas de unión a antígeno que activan el receptor de leptina
EA201891331A1 (ru) Бипаратопные полипептиды - антагонисты передачи сигнала wnt в опухолевых клетках
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
JO3182B1 (ar) مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
JO3791B1 (ar) تركيبات و طرق الأجسام المضادة المستهدفة لـ bmp6
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
EA201691541A1 (ru) Новые анти-baff антитела
EA201992206A1 (ru) Моноклональное антитело к pd-l1
EA201692473A1 (ru) Способы получения замещенных нуклеотидных аналогов
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
EA201492163A1 (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К TrkA, СОДЕРЖАЩИЕ АМИНОКИСЛОТНЫЕ ЗАМЕНЫ
CO2020000090A2 (es) Cromatografia
PH12017500094A1 (en) Novel anti-human tie-2 antibody
EA202091259A1 (ru) Способ получения опикапона и его интермедиатов
EA201691367A1 (ru) Кристаллические формы дималеата афатиниба
EA201890434A1 (ru) Антитела к cd154 и способы их применения
EA202092088A1 (ru) Антитела анти-phf-тау и их применение
EA201792328A1 (ru) Способ очистки белков
UY37377A (es) Anticuerpos multiespecíficos que facilitan el emparejamiento selectivo de cadenas ligeras